Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Marathon, on the surface, can be a tad overwhelming. However, when you break the game down, we've found it becomes much more straightforward to get into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results